127 related articles for article (PubMed ID: 17329869)
1. The effects of external heating on the permeation of oxybutynin through human epidermal membrane.
Mizushima H; Inoue K; Ishizuka H
Biol Pharm Bull; 2007 Mar; 30(3):612-5. PubMed ID: 17329869
[TBL] [Abstract][Full Text] [Related]
2. Membrane permeation-controlled transdermal delivery system design. Influence of controlling membrane and adhesive on skin permeation of isosorbide dinitrate.
Seki T; Kawaguchi T; Sugibayashi K; Juni K; Morimoto Y
Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):740-3. PubMed ID: 2347017
[TBL] [Abstract][Full Text] [Related]
3. Transdermal drug delivery treatment for overactive bladder.
Dmochowski RR; Starkman JS; Davila GW
Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
[TBL] [Abstract][Full Text] [Related]
4. Investigation of molecular mobility of pressure-sensitive-adhesive in oxybutynin patch in vitro and in vivo: Effect of sorbitan monooleate on drug release and patch mechanical property.
Wang W; Liu C; Luo Z; Wan X; Fang L
Eur J Pharm Sci; 2018 Sep; 122():116-124. PubMed ID: 29928984
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.
Zobrist RH; Quan D; Thomas HM; Stanworth S; Sanders SW
Pharm Res; 2003 Jan; 20(1):103-9. PubMed ID: 12608543
[TBL] [Abstract][Full Text] [Related]
6. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
Sahai A; Mallina R; Dowson C; Larner T; Khan MS
Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
[TBL] [Abstract][Full Text] [Related]
8. [Studies on transdermal delivery system of isosorbide dinitrate].
Ji AM; Jiang XT; Wang XF; Zou HQ
Yao Xue Xue Bao; 1992; 27(11):858-63. PubMed ID: 1300032
[TBL] [Abstract][Full Text] [Related]
9. Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome.
Sheng Y; Zhang S; Ling J; Hu C; Zhang Z; Lv H
Pharm Dev Technol; 2022 Apr; 27(4):459-468. PubMed ID: 35575444
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
[TBL] [Abstract][Full Text] [Related]
11. New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin.
Nicoli S; Penna E; Padula C; Colombo P; Santi P
Int J Pharm; 2006 Nov; 325(1-2):2-7. PubMed ID: 16860952
[TBL] [Abstract][Full Text] [Related]
12. Electron beam irradiation: a novel technology for the development of transdermal system of isosorbide dinitrate.
Kotiyan PN; Vavia PR; Bhardwaj YK; Sabarwal S; Majali AB
Int J Pharm; 2004 Feb; 270(1-2):47-54. PubMed ID: 14726121
[TBL] [Abstract][Full Text] [Related]
13. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.].
Merino Salas S
Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041
[TBL] [Abstract][Full Text] [Related]
14. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
Zhao JH; Fu JH; Wang SM; Su CH; Shan Y; Kong SJ; Wang Y; Lu WL; Zhang H; Zhang S; Li L; Zhang EH; Wang L; Pei QL; Wang JC; Zhang X; Zhang Q
Int J Pharm; 2007 Jun; 337(1-2):88-101. PubMed ID: 17267147
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.
Mizushima H; Takanaka K; Abe K; Fukazawa I; Ishizuka H
Xenobiotica; 2007 Jan; 37(1):59-73. PubMed ID: 17178634
[TBL] [Abstract][Full Text] [Related]
16. Oxybutynin gel for the treatment of overactive bladder.
Gomelsky A; Dmochowski RR
Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
[TBL] [Abstract][Full Text] [Related]
17. Effect of heat on the percutaneous absorption and skin retention of three model penetrants.
Akomeah F; Nazir T; Martin GP; Brown MB
Eur J Pharm Sci; 2004 Feb; 21(2-3):337-45. PubMed ID: 14757507
[TBL] [Abstract][Full Text] [Related]
18. The value of oxybutynin in transdermal patches for treating overactive bladder.
Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
[TBL] [Abstract][Full Text] [Related]
19. [Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.].
Vozmediano-Chicharro R; Blasco Hernández P; Madurga-Patuel B
Arch Esp Urol; 2017 Jul; 70(6):561-569. PubMed ID: 28678009
[TBL] [Abstract][Full Text] [Related]
20. Oxybutynin permeation in skin: the influence of drug and solvent activity.
Santos P; Watkinson AC; Hadgraft J; Lane ME
Int J Pharm; 2010 Jan; 384(1-2):67-72. PubMed ID: 19799975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
